Key clinical point: Intracranial hemorrhage (ICH) is still a deadly complication affecting survival in patients with newly diagnosed nonacute promyelocytic acute myeloid leukemia (AML) receiving intensive induction chemotherapy (IIC) despite routine prophylactic platelet substitution.
Major finding: Overall, 4% of patients developed ICH. Patients with ICH vs. without had worse overall survival (median, 20.1 vs. 104.8 months; P = .0079) with female sex (adjusted odds ratio [aOR] 3.79; P = .03), low thrombocyte (aOR 1.2; P = .03), and fibrinogen levels at admission (aOR 1.62; P = .03) being risk factors for ICH.
Study details: This retrospective study included 423 patients with newly diagnosed nonacute promyelocytic AML hospitalized for IIC with routine platelet transfusions at <10 thrombocytes/nL.
Disclosures: This study did not receive any funding. The authors declared no conflict of interests.
Source: Koschade SE et al. Eur J Haematol. 2021(Oct 29). Doi: 10.1111/ejh.13718.